Drugs / CK-4021586
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05877053 | May 2023 → Nov 2024 | — | Cytokinetics | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06793371 | Feb 2025 → Sep 2026 overdue | symptomatic heart failure | Cytokinetics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | Cytokinetics | Results Cytokinetics Announces Data From Phase 1 Study of CK-4021586 cytokinetics.com ↗
The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple oral doses of CK-586. |
| 2024-05-08 | Cytokinetics | Results Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 cytokinetics.com ↗
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). |
| 2023-10-19 | Cytokinetics | Results Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day cytokinetics.com ↗
New Pre-Clinical Data for CK-586 Shows Improved Diastolic Function and Reduced Cardiac Fibrosis in Animal Model of HFpEF |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | Cytokinetics | Cytokinetics Announces Data From Phase 1 Study of CK-4021586 cytokinetics.com ↗ |
| 2024-05-08 | Cytokinetics | Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 cytokinetics.com ↗ |
| 2023-10-19 | Cytokinetics | Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day cytokinetics.com ↗ |
| 2023-05-11 | Cytokinetics | Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586 cytokinetics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CK-4021586 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877053 ↗ |
| Route | Oral | “CK-4021586 administered orally” NCT06793371 ↗ |